

India | Equity Research | Company Update

Cera Sanitaryware

Sanitaryware

Demand remains tepid; hopeful of pick-up in FY26

We recently interacted with management of Cera Sanitaryware (CRS). Takeaways: 1) Demand scenario has remained sluggish; while the project segment continues to see healthy traction, retail yet remains slow. Management expects low-single-digit YoY revenue growth for FY25 and is hopeful of better growth in FY26, as many of the earlier-launched projects are expected to see completion. 2) Management believes their operating margins would be in the range of $\sim 16-17\%$ going ahead as demand improves and the complete effect of price increases is passed on to the market. Also, the focus on premium products that have better margins should aid profitability ahead. Maintain estimates and BUY with an unchanged Dec'25E TP of INR 7,902.

Demand trends remain tepid

As per our interaction with management, demand trends are yet sluggish. Demand from the projects segment remains healthy; however, the retail segment is yet to pick up. Management expects low-single-digit growth in FY25 and is hopeful of a better FY26 driven by the completion of many projects that were launched earlier. Contribution of the projects business may rise a marginal 1–3% in FY25 (from ~35% in FY24); CRS does not expect any strain on its balance sheet, as these sales are routed through dealers, and thus, credit terms are tightly followed. CRS is focusing on increasing its presence in the luxury segment through its three major brands: LUXE, SENATOR and LUSTRE. It has tied-up with influencers in major markets to penetrate this segment and would launch more SKUs and targets to derive ~10% of revenue from this segment by FY27. CRS plans to open 55–60 stores of Senator and 100 stores of LUXE by FY26. Management maintains its FY27 revenue target of ~INR 29bn. We model a revenue CAGR of 9.2% over FY24–27E.

Margins to improve to ~16-17%

CRS management believes it can achieve $\sim 16-17\%$ OPM going ahead as demand improves and it can pass on the complete price hike ($\sim 6\%$ taken in Sept'24) in faucetware ($\sim 3\%$ done TD). Also, improved contribution from luxury segment should aid margins going ahead. We have modelled OPM of 14.5-15.8% over FY25-27E (vs. avg. OPM of $\sim 15.2\%$ over FY12-24).

Financial Summary

Y/E March (INR mn)	FY24A	FY25E	FY26E	FY27E
Net Revenue	18,706	18,900	21,371	24,358
EBITDA	2,949	2,745	3,315	3,860
EBITDA %	15.8	14.5	15.5	15.8
Net Profit	1,967	2,155	2,611	3,012
EPS (INR)	152.5	167.1	202.4	233.5
EPS % Chg YoY	2.9	9.6	21.1	15.4
P/E (x)	37.1	33.9	28.0	24.2
EV/EBITDA (x)	22.0	23.6	19.3	16.5
RoCE (%)	13.5	12.1	14.1	14.9
RoE (%)	15.6	15.9	18.2	18.7

Arun Baid

arun.baid@icicisecurities.com +91 22 6807 7235

Sohil Kaura

sohil.kaura@icicisecurities.com

Market Data

Market Cap (INR)	73bn
Market Cap (USD)	853mn
Bloomberg Code	CRS IN
Reuters Code	CERA.BO
52-week Range (INR)	11,500 /5,060
Free Float (%)	45.0
ADTV-3M (mn) (USD)	1.6

Price Performance (%)	3m	6m	12m
Absolute	(22.9)	(31.9)	(17.3)
Relative to Sensey	(22.3)	(23.8)	(243)

ESG Score	2023	2024	Change
ESG score	69.7	NA	NA
Environment	49.7	NA	NA
Social	70.6	NA	NA
Governance	81.6	NA	NA

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

Previous Reports

13-02-2025: <u>Q3FY25 results review</u> 11-12-2024: <u>Company Update</u>



Valuation and view


CRS' near-term demand outlook remains tepid but with real estate market expected to remain healthy as many real estate projects from CY25 (which were launched in CY22 and earlier) are expected to get completed, demand for bathware segment is expected to be buoyant. We believe CRS is poised to benefit from the uptick in housing market due to its wide distribution, strong brand, comprehensive product portfolio and healthy balance sheet. Maintain estimates and **BUY** rating on the stock with an unchanged Dec'25E TP of INR 7,902, set at 35x Dec'26E PER.

Exhibit 1: Robust real estate launches in the past couple of years

Real Estate launches (in units)	CY19	CY20	CY21	CY22	CY23	CY24	5-year CAGR
NCR	35,280	18,520	31,706	25,355	36,740	53,000	8.5%
MMR	77,990	30,290	56,883	1,24,652	1,57,700	1,34,500	11.5%
Bengaluru	39,930	21,430	30,646	49,196	54,440	71,000	12.2%
Pune	46,100	23,930	39,869	64,343	83,630	60,500	5.6%
Hyderabad	14,840	21,100	51,470	68,007	76,340	58,300	31.5%
Chennai	13,000	9,160	12,373	9,994	20,140	20,900	10.0%
Kolkata	9,420	3,530	13,746	16,088	16,790	14,200	8.6%
Total	2,36,560	1,27,960	2,36,693	3,57,635	4,45,780	4,12,500	11.8%
YoY (%)	21%	-46%	85%	51%	25%	-7.5%	


Source: I-Sec research, Company data

Exhibit 2: Consol. revenue CAGR of 9.2% over FY24-27E aided by growth in faucetware segment




Source: I-Sec research, Company data

Exhibit 3: Sanitaryware dominates revenue mix; faucetware to improve share by 500bps over FY24-27E




Source: I-Sec research, Company data

Exhibit 4: EBITDA CAGR at 9.4% over FY24-27E



Source: I-Sec research, Company data


Exhibit 5: EBITDA margin to remain healthy



Source: I-Sec research, Company data




Exhibit 6: High A&P spends have enabled strong brand creation




Source: I-Sec research, Company data

Exhibit 8: Retail dominates sales mix (FY24)




Source: I-Sec research, Company data

Exhibit 10: APAT CAGR likely at 15.3% over FY24-27E




Source: I-Sec research, Company data

Exhibit 7: Dealer network grew ~4.2x over FY17-FY24




Source: I-Sec research, Company data

Exhibit 9: Strong presence in tier-3 and below markets



Source: I-Sec research, Company data

Exhibit 11: RoE to remain healthy over FY25-27E



Source: I-Sec research, Company data




Valuation

CRS is one of the major organised sanitaryware players in India. Over the years, the company has expanded its product portfolio from sanitaryware to tiles, faucets and wellness goods, becoming a one-stop bathroom solution provider. It has significant presence in tier-2 and tier-3 markets with strong brand name and wide distribution.

CRS is expected to witness EBIDTA/APAT CAGRs of 9.4%/15.3% during FY24–27E, with continued strong balance sheet and healthy return ratios (RoE of 18.7% in FY26E). Maintain **BUY** with an unchanged Dec'25E target price of INR 7,902 set at an 35x Dec'26E P/E, in line with the historical 5-year average, 1-year forward P/E.

Exhibit 12: 1-year forward PE band



Source: I-Sec research, Company data

Key downside risks

- Unexpected slowdown in housing market would adversely affect business.
- Higher raw material prices may adversely affect profitability and demand.
- Higher-than-expected competitive intensity which may adversely affect growth/margins.

Exhibit 13: Shareholding pattern

%	Jun'24	Sep'24	Dec'24
Promoters	54.5	54.4	54.4
Institutional investors	28.8	29.0	28.4
MFs and others	6.8	5.6	5.7
Insurance	0.5	0.5	0.6
FIIs	21.5	22.9	22.2
Others	16.7	16.6	17.2

Exhibit 14: Price chart



Source: Bloomberg, I-Sec research Source: Bloomberg, I-Sec research

India | Institutional Equity Research



Financial Summary

Exhibit 15: Profit & Loss

(INR mn, year ending March)

	FY24A	FY25E	FY26E	FY27E
Net Sales	18,706	18,900	21,371	24,358
Operating Expenses	15,757	16,154	18,056	20,498
EBITDA	2,949	2,745	3,315	3,860
EBITDA Margin (%)	15.8	14.5	15.5	15.8
Depreciation & Amortization	365	408	436	486
EBIT	2,584	2,337	2,879	3,375
Interest expenditure	58	81	26	23
Other Non-operating	58	671	691	738
Income				
Recurring PBT	2,584	2,927	3,545	4,090
Less: Taxes	(775)	(749)	(908)	(1,047)
PAT	1,809	2,177	2,638	3,043
Profit / (Loss) from	_	_	_	_
Associates				
Less: Minority Interest	(23)	(22)	(27)	(31)
Extraordinaries (Net)	605	-	-	-
Net Income (Reported) Net Income (Adjusted)	2,390 1,967	2,155 2,155	2,611 2,611	3,012 3,012

Source Company data, I-Sec research

Exhibit 16: Balance sheet

(INR mn, year ending March)

(IIVI IIII, year enaing March)				
	FY24A	FY25E	FY26E	FY27E
Assets				
Inventories	3,636	3,762	4,205	4,717
Cash & cash eqv.	8,382	8,431	9,220	9,283
Sundry Debtors	2,026	2,019	2,225	2,536
Other Current Assets	527	570	644	734
Trade payables	1,790	1,850	2,091	2,384
Other Current Liabilities	2,153	2,163	2,446	2,788
Net Current Assets	10,628	10,770	11,757	12,099
Investments	31	31	31	31
Net Fixed Assets	3,629	3,621	4,155	5,670
Other Non Current Assets	225	225	225	225
Total Assets	14,512	14,646	16,168	18,024
Liabilities				
Borrowings	205	170	50	50
Other Non Current	722	754	786	786
Liabilities	122	754	786	786
Total Liabilities	927	924	836	836
Equity Share Capital	65	64	64	64
Reserves & Surplus	13,393	13,508	15,091	16,916
Total Net Worth	13,458	13,573	15,155	16,981
Minority Interest	128	150	176	207
Total Liabilities & Net Worth	14,512	14,646	16,168	18,024

Source Company data, I-Sec research

Exhibit 17: Quarterly trend

(INR mn, year ending March)

	Mar-24	Jun-24	Sep-24	Dec-24
Net Sales	5,488	4,007	4,926	4,523
% growth (YOY)	2.5	-6.5	6.4	3.1
EBITDA	950	581	721	615
Margin %	17.3	14.5	14.6	13.6
Other Income	157	159	178	117
Extraordinaries	0	0	0	0
Adjusted Net Profit	749	471	680	458

Source Company data, I-Sec research

Exhibit 18: Cashflow statement

(INR mn, year ending March)

	FY24A	FY25E	FY26E	FY27E
Operating Cashflow	2,946	2,547	2,934	3,280
Working Capital Changes	40	(92)	(198)	(279)
Capital Commitments	(691)	(400)	(970)	(2,000)
Free Cashflow	2,255	2,147	1,964	1,280
Other investing cashflow	0	-	-	-
Cashflow from Investing	(691)	(400)	(970)	(2,000)
Activities	(001)	(400)	(370)	(2,000)
Issue of Share Capital	-	(1)	-	-
Inc (Dec) in Borrowings	(49)	(35)	(120)	-
Dividend paid	(780)	(762)	(1,055)	(1,217)
Others	97	(1,300)	-	-
Cash flow from Financing Activities	(733)	(2,097)	(1,175)	(1,217)
Chg. in Cash & Bank balance	1,523	49	789	63
Closing cash & balance	8,382	8,431	9,220	9,283

Source Company data, I-Sec research

Exhibit 19: Key ratios

(Year ending March)

	FY24A	FY25E	FY26E	FY27E
Per Share Data (INR)				
Reported EPS	185.3	167.1	202.4	233.5
Adjusted EPS (Diluted)	152.5	167.1	202.4	233.5
Cash EPS	180.8	198.8	236.2	271.2
Dividend per share (DPS)	60.0	59.1	81.8	94.4
Book Value per share (BV)	1,043.5	1,052.3	1,175.1	1,316.6
Dividend Payout (%)	39.3	35.4	40.4	40.4
Growth (%)				
Net Sales	3.7	1.0	13.1	14.0
EBITDA	0.4	(6.9)	20.8	16.4
EPS (INR)	2.9	9.6	21.1	15.4
Valuation Ratios (x)				
P/E	37.1	33.9	28.0	24.2
P/CEPS	31.3	28.5	24.0	20.9
P/BV	5.4	5.4	4.8	4.3
EV / EBITDA	22.0	23.6	19.3	16.5
EV / Sales	3.5	3.4	3.0	2.6
Dividend Yield (%)	1.1	1.0	1.4	1.7
Operating Ratios				
Gross Profit Margins (%)	52.8	53.0	53.0	53.0
EBITDA Margins (%)	15.8	14.5	15.5	15.8
Effective Tax Rate (%)	30.0	25.6	25.6	25.6
Net Profit Margins (%)	10.5	11.4	12.2	12.4
NWC / Total Assets (%)	12.2	12.5	12.3	12.1
Net Debt / Equity (x)	(0.6)	(0.6)	(0.6)	(0.5)
Net Debt / EBITDA (x)	(2.8)	(3.0)	(2.8)	(2.4)
Profitability Ratios				
RoCE (%) (post-tax)	13.5	12.1	14.1	14.9
RoE (%)	15.6	15.9	18.2	18.7
Cash Conversion Cycle				
(on net sales)				
Inventory Turnover Days	71	73	72	71
Receivables Days	40	39	38	38
Payables Days	35	36	36	36
Source Company data, I-Sec rese	arch			

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com and Kadambari_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Arun Baid, MBA; Sohil Kaura, M.Com (Finance); authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

 $Name of the Compliance of ficer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, \ \textbf{E-mail Address}: \underline{compliance of ficer@icicisecurities.com}$

 $For any queries or grievances: \underline{\textit{Mr. Bhavesh Soni}} \ \ Email \ address: \underline{\textit{headservicequality@icicidirect.com}} \ \ Contact \ \ Number: 18601231122$